Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

J F Liu, W T Barry, M Birrer, J-M Lee, R J Buckanovich, G F Fleming, B J Rimel, M K Buss, S R Nattam, J Hurteau, W Luo, J Curtis, C Whalen, E C Kohn, S P Ivy, U A Matulonis, J F Liu, W T Barry, M Birrer, J-M Lee, R J Buckanovich, G F Fleming, B J Rimel, M K Buss, S R Nattam, J Hurteau, W Luo, J Curtis, C Whalen, E C Kohn, S P Ivy, U A Matulonis

Abstract

Background: Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an oral anti-angiogenic. In the primary analysis of this phase II study, combination cediranib/olaparib improved progression-free survival (PFS) compared with olaparib alone in relapsed platinum-sensitive ovarian cancer. This updated analysis was conducted to characterize overall survival (OS) and update PFS outcomes.

Patients and methods: Ninety patients were enrolled to this randomized, open-label, phase II study between October 2011 and June 2013 across nine United States-based academic centers. Data cut-off was 21 December 2016, with a median follow-up of 46 months. Participants had relapsed platinum-sensitive ovarian cancer of high-grade serous or endometrioid histology or had a deleterious germline BRCA1/2 mutation (gBRCAm). Participants were randomized to receive olaparib capsules 400 mg twice daily or cediranib 30 mg daily and olaparib capsules 200 mg twice daily until disease progression.

Results: In this updated analysis, median PFS remained significantly longer with cediranib/olaparib compared with olaparib alone (16.5 versus 8.2 months, hazard ratio 0.50; P = 0.007). Subset analyses within stratum defined by BRCA status demonstrated statistically significant improvement in PFS (23.7 versus 5.7 months, P = 0.002) and OS (37.8 versus 23.0 months, P = 0.047) in gBRCA wild-type/unknown patients, although OS was not statistically different in the overall study population (44.2 versus 33.3 months, hazard ratio 0.64; P = 0.11). PFS and OS appeared similar between the two arms in gBRCAm patients. The most common CTCAE grade 3/4 adverse events with cediranib/olaparib remained fatigue, diarrhea, and hypertension.

Conclusions: Combination cediranib/olaparib significantly extends PFS compared with olaparib alone in relapsed platinum-sensitive ovarian cancer. Subset analyses suggest this margin of benefit is driven by PFS prolongation in patients without gBRCAm. OS was also significantly increased by the cediranib/olaparib combination in this subset of patients. Additional studies of this combination are ongoing and should incorporate analyses based upon BRCA status.

Trial registration: Clinicaltrials.gov Identifier NCT0111648.

Keywords: PARP inhibitors; antiangiogenic therapies; combination targeted therapies; ovarian cancer.

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Updated CONSORT diagram. PFS, progression-free survival.
Figure 2.
Figure 2.
Kaplan–Meier curves of (A) updated progression-free survival by the treatment arm and (B) overall survival by the treatment arm.
Figure 3.
Figure 3.
Kaplan–Meier curves of updated progression-free survival and overall survival in (A) germline BRCA-mutated patients and (B) germline BRCA wild-type/unknown patients.

References

    1. Siegel RL, Miller KD, Jemal A.. Cancer statistics, 2018. CA Cancer J Clin 2018; 68(1): 7–30.
    1. Zejula (niraparib) [package insert]; (29 January 2019, date last accessed).
    1. Zejula (niraparib) [EMA Authorisation]; (29 January 2019, date last accessed).
    1. Lynparza (olaparib) [package insert]; (29 January 2019, date last accessed).
    1. Rubraca (rucaparib) [package insert]; (29 January 2019, date last accessed).
    1. Lynparza (olaparib) [EMA Authorisation]; (29 January 2019, date last accessed).
    1. Rubraca (rucaparib) [EMA Authorisation]; (29 January 2019, date last accessed).
    1. Avastin (bevacizumab) [package insert]; (29 January 2019, date last accessed).
    1. Avastin (bevacizumab) [EMA Authorisation]; (29 January 2019, date last accessed).
    1. Bindra RS, Gibson SL, Meng A. et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 2005; 65(24): 11597–11604.
    1. Bindra RS, Schaffer PJ, Meng A. et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004; 24(19): 8504–8518.
    1. Chan N, Bristow RG.. “Contextual” synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res 2010; 16(18): 4553–4560.
    1. Hegan DC, Lu Y, Stachelek GC. et al. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci USA 2010; 107(5): 2201–2206.
    1. Ivy SP, de Bono J, Kohn EC.. The ‘Pushmi-Pullyu’ of DNA REPAIR: clinical synthetic lethality. Trends Cancer 2016; 2(11): 646–656.
    1. Liu JF, Barry WT, Birrer M. et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014; 15(11): 1207–1214.
    1. Schemper M, Smith TL.. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17(4): 343–346.
    1. Lee JM, Trepel JB, Choyke P. et al. CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer. Front Oncol 2015; 5: 123.
    1. Mirza MR, Wang J, Mau-Sorensen M. et al. A Phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24/AVANOVA1). In Proceedings from the 2017 ESMO Congress (Abstr 935P), 8–12 September, 2017. Madrid, Spain 2017.
    1. Platine, Avastin, and OLAparib in 1st Line (PAOLA-1); (29 January 2019, date last accessed).
    1. Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients with Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer (MITO25); (29 January 2019, date last accessed).
    1. Phase 2, A Study of Niraparib Combined with Bevacizumab Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy; (29 January 2019, date last accessed).
    1. Liu JF, Tolaney SM, Birrer M. et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 2013; 49(14): 2972–2978.
    1. Ledermann JA, Embleton AC, Raja F. et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 387(10023): 1066–1074.
    1. Olaparib or Cediranib Maleate and Olaparib Compared with Standard Platinum-Based Chemotherapy in Treating Patients with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; (29 January 2019, date last accessed).
    1. Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; (29 January 2019, date last accessed).
    1. Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients (ICON9); (29 January 2019, date last accessed).

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi